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Objective: To gather additional data on the ability to detect subchromosomal
abnormalities of various sizes in single fetal cells isolated from maternal blood, using
low‐coverage shotgun next‐generation sequencing for cell‐based noninvasive prena-
tal testing (NIPT).
Method: Fetal trophoblasts were recovered from approximately 30 mL of maternal
blood using maternal white blood cell depletion, density‐based cell separation, immuno-
fluorescence staining, and high‐resolution scanning. These trophoblastic cellswere picked
as single cells and underwent whole genome amplification for subsequent genome‐wide
copy number analysis and genotyping to confirm the fetal origin of the cells.
Results: Applying our fetal cell isolation method to a series of 125 maternal blood
samples, we detected on average 4.17 putative fetal cells/sample. The series included
15 cases with clinically diagnosed fetal aneuploidies and five cases with
subchromosomal abnormalities. This method was capable of detecting findings that
were 1 to 2 Mb in size, and all were concordant with the microarray or karyotype data
obtained on a fetal sample. A minority of fetal cells showed evidence of genome
degradation likely related to apoptosis.
Conclusion: We demonstrate that this cell‐based NIPT method has the capacity to
reliably diagnose fetal chromosomal abnormalities down to 1 to 2 Mb in size.1 | INTRODUCTION
In recent years, the field of prenatal testing has been transformed with
the clinical implementation of cell‐free DNA (cfDNA)‐based analysis,
known as noninvasive prenatal testing (NIPT). Despite its clearly- - - - - - - - - - - - - - - - - - - - - - - - - - -
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What is already known about this
topic?
• Fetal trophoblastic cells can be isolated from maternal
blood and be used for the detection of fetal
aneuploidies and copy number variants. The data on
the detection of subchromosomal delestions and
duplications is currently limited.
What does this study add?
• Cell‐based NIPT can be used for the detection of copy
number abnormalities of greater than or equal to 1 Mb
in the fetus by low‐coverage next‐generation
sequencing after single cell whole genome
amplification. Data are provided here for five cases in
which different subchromosomal deletions and
duplications ranging from 1.2 to 18.9 Mb were
detected in single cells.
1070 VOSSAERT ET AL.copy number variants (CNVs). cfDNA‐based NIPT is currently only rec-
ommended for common fetal aneuploidies but not for screening for
microdeletions/duplications in statements from professional societies.1,2
During a normal pregnancy, only 5% to 20% of the total cfDNA pool is of
fetal origin, referred to as the fetal fraction.3 The current NIPTmethodol-
ogy thus relies on identifying a chromosomal abnormality in an amalgam-
ation of maternal and fetal DNA fragments, which can lead to false
positive results, and its performance can be affected by a below average
fetal fraction (<4%). cfDNA‐based NIPT is also potentially influenced by
maternal chromosomal mosaicism or maternal malignancies.4 It thus
remains a screening test requiring diagnostic testing for confirmation of
positive results. Since the clinical implementation of cfDNA‐based NIPT,
the number of Chorionic villus sampling (CVS)/amniocentesis procedures
performed has decreased substantially over recent years.5-7 While this
reduces the procedure‐related risk for pregnancy loss, it also leads to fail-
ure to diagnose clinically significant subchromosomal abnormalities such
as deletion and duplication syndromes, easily detectable with chromo-
somal microarray (CMA), the current standard diagnostic test of DNA
extracted from amniotic fluid or chorionic villi.
In contrast, cell‐based NIPT offers a more attractive alternative if
it can be performed reproducibly and at reasonable cost. Although
cell‐based NIPT also has limitations such as the risk of too few cells
recovered, the specific isolation of multiple individual fetal cells from
the maternal circulation offers the advantage of providing pure fetal
DNA, free of maternal DNA contamination. As such, the fetal genome
can be analyzed at a higher resolution, allowing for the detection of
CNVs as small as 1 to 2 Mb in size. This would thus allow for increased
accuracy and improved positive and negative predictive values com-
pared with cfDNA‐based NIPT in detecting microdeletion syndromes
that are responsible for a range of rare conditions including some
cases of autism and intellectual disability and can be detected in up
to 1.7% of amniotic fluid or CVS samples from pregnancies without
fetal anomalies.8 Additionally, the analysis of multiple individual fetal
cells from one sample yields data replicates, creating the potential
for a higher test result confidence and to identify two different fetal
genotypes in case of confined placental mosaicism.
Multiple recent publications9-12 substantiate the feasibility of this
approach and show concordant results with the correspondingmicroar-
ray and karyotype data from invasive diagnostic testing, including a case
in which the fetus was affected with a 2.7‐Mb deletion of chromosome
15.9 This was the first indication that cell‐based NIPT has the capacity
to perform at the resolution required for a clinically diagnostic prenatal
test. The published methods describe the enrichment of fetal tropho-
blastic cells, by either depletion of maternal cells9 or specific fetal cell
positive enrichment,10-12 for downstream genome‐wide CNV analysis.
These publications, along with earlier reports of a high failure rate when
attempting to isolate fetal nucleated red blood cells (fnRBCs),13 and our
own unpublished failed fnRBC attempts guided our decision to focus
initially on circulating trophoblasts. Fetal nRBCs would certainly be
attractive and avoid confined placental mosaicism, if successful and
consistent recovery and analysis can be achieved, but this has not been
demonstrated so far. In this follow‐up report, we present multiple addi-
tional cases processed with the aforementioned depletion protocol. In
this method, fetal trophoblasts are isolated and analyzed, after deple-
tion of maternal white blood cells (WBCs), immunostaining, high‐resolution scanning, visual verification of target cells, subsequent whole
genome amplification (WGA) and low coverage (0.3‐0.6X, 100 BP
paired‐end reads) single cell next‐generation sequencing (NGS).
2 | METHODS
2.1 | Sample collection
Blood samples from pregnant women were collected after informed
consent, under a protocol approved by the Institutional Review Boards
of Baylor College of Medicine and Columbia University. The study sub-
jects were recruited following routine prenatal genetic counseling, and
in many cases also underwent CVS or amniocentesis followed by con-
ventional chromosome analysis and/or CMA. Approximately 30 mL
maternal venous blood was drawn into blood collection tubes contain-
ing a proprietary preservative (RareCyte) for trophoblast enrichment.
An additional 4 mL was collected in Ethylene‐Diamine‐Tetra‐acetic acid
(EDTA) tubes for maternal genomic DNA (gDNA) extraction and fetal
cfDNA collection for fetal sex determination. When possible, a 2‐mL
blood sample in EDTA or saliva (Oragene) from the father was also col-
lected. The tubes for fetal cell isolation were kept overnight at room
temperature or shipped by overnight carrier at ambient temperature
until further processing the next day. Maternal gDNA extraction (and
paternal when available), fetal cfDNA extraction, and quantitative poly-
merase chain reaction (PCR) for fetal sex determinationwere performed
as previously described.9 Table 1 summarizes this sample series' charac-
teristics, more detailed information is available in theTable S1.
2.2 | Trophoblast enrichment and isolation
Trophoblasts were enriched and stained as previously described,9 with
the inclusion of a maternal WBC depletion step for all samples. The
TABLE 1 Sample series characteristics
125 Blood Samples Collected from 122 Pregnant Women (Including
Three Redraws)
Plurality Singleton 118 pregnancies 96.7%
Twin 4 pregnancies 3.3%
Fetal sex Female 53 pregnancies 43.4%
Male 65 pregnancies 53.3%
Twin – F + F 1 pregnancy 0.8%
Twin – F + M 2 pregnancies 1.6%
Twin – M + M 1 pregnancy 0.8%
Maternal age Range 19‐41 y/o
Median 32 y/o
Maternal BMI Range 18.90‐45.89 kg/m2
Median 25.34 kg/m2
GA at sampling Range 10 weeks and 2 days
to 35 weeks and 1 day
Median 12 weeks and 6 days
Recruitment Houston 87 samples 69.6%
New York 38 samples 30.4%
Paternal samples Not available for 71 pregnancies 58.2%
Available for 51 pregnancies 41.8%
Blood: 44 samples
(84.8%)
Saliva: 7 samples (15.2%)
Diagnostic
testing
No testing 44 women 36.1%
CVS 42 women (4 samples PP) 34.4%
Amniocentesis 33 women (3 samples PP) 27.0%
Both 3 women 2.5%
Abbreviations: F, female; M, male; GA, gestation age; PP, postprocedure (=
blood sample collected few minutes to 2 hours after diagnostic procedure).
Of note, BMI data were only available for 103 out of 125 samples
(=82.4%).
TABLE 2 Fetal trophoblast yield
Overview Fetal Trophoblast Identification
Average cells identified
by microscopy
4.17 cells/sample
(range 0‐38 cells/sample)
0.18 cells/mL maternal blood
(range 0‐1.58 cells/mL)
Trophoblast distribution
(total of 125 samples collected)
0 cells 23 samples 18.4%
1 cells 24 samples 19.2%
2 cells 11 samples 8.8%
3 or 4 cells 23 samples 18.4%
5 cells or more 44 samples 35.2%
VOSSAERT ET AL. 1071amount of depleted maternal WBCs ranged from 79.6% to 99.3%,
with an average of 91.5% based on cell counting. After the depletion
step, all nucleated cells were separated based on density centrifuga-
tion, fixed, and stained. All samples were spread on CyteSlides
(RareCyte, 800 000 cells/well) and scanned on the CyteFinder instru-
ment (RareCyte), as previously described.9 All putative trophoblasts
meeting the internally specified criteria (specific nuclear morphology,
cytokeratin‐positive staining in a defined pattern, and WBC marker
CD45‐negative) were picked as single cells and deposited in 2 uL of
PBS in a PCR tube and stored at −80°C until further processing.
We applied this protocol to 125 samples from 122women (three of
whom had two blood draws), including 15 cases with a fetal aneuploidy
and five in which a fetal subchromosomal abnormality was diagnosed.
2.3 | Whole genome amplification and genotyping
Single cells were processed with the PicoPLEXWGA kit (Rubicon, now
Takara Bio) as previously described.9 All purified WGA products were
stored at −20°C until further use.
A genotyping assay was developed for the confirmation of fetal
origin of the isolated fetal cell candidates (Zhuo et al manuscript in
preparation). With this NGS‐based assay, a series of informative sin-
gle‐nucleotide polymorphisms (SNPs) in the trophoblast WGA prod-
ucts are analyzed and compared with the SNP profile of the
maternal and when available paternal gDNA. A cell is scored as being
fetal when the corresponding WGA products show two or more poly-
morphic alleles not present in the maternal gDNA; one such allele is
scored as likely fetal. Based on data from male pregnancies, the priorprobability that a female cell from a female pregnancy is fetal is
89%, and using a Bayesian calculation, the presence of one or two
nonmaternal alleles gives a very high probability that the cell is fetal.2.4 | CNV analysis
Sequencing for genome‐wide copy number detection and subsequent
analysis was done as previously described.9 In short, library prepara-
tion was started from 300 ng of WGA product after which paired‐
end, whole genome sequencing was performed on a HiSeq platform
(Illumina), aiming for 5 to 10 x 106 unique reads per cell (100 BP read
length), giving a genome coverage of about 0.3 to 0.6X. An in house‐
developed web tool was used to generate a view with both a whole
genome (1 Mb bin size) and detailed single chromosome plots
(100 kb bins). Similar results are obtained with other commercially
available tools (eg, BioDiscovery Inc.). CNV analysis was not done
for all cases.
A more detailed methods description is provided in the Data S1.3 | RESULTS
3.1 | Fetal trophoblast yield
A range of 0 to 38 trophoblastic cells per sample was identified by
microscopy, corresponding to an average of 4.17 cells/sample or
0.18 cells/mL of maternal blood (Table 2). For the four twin pregnancy
samples, 12, 9, 14, and 15 trophoblastic cells were found, correspond-
ing to 0.50, 0.50, 0.58, and 0.63 cells/mL respectively. For 27 samples,
some fetal cells appeared in a cluster of two to five cells (Table S1).
These grouped cells were mostly picked as one cluster and also ana-
lyzed as such. All other trophoblasts undergoing CNV assessment
were analyzed as single cells.
For male pregnancies (confirmed by clinical information and fetal
sex determination based on cfDNA PCR), the fetal origin of the cells
can be assessed by NGS analysis of X and Y copy number. Out of
the 103 male putative trophoblasts analyzed, 11 showed an XX com-
plement instead of XY and were thus of likely maternal origin. For
female fetuses and twin pregnancies, 188 cells out of 289 putative
cells were genotyped, and the fetal or likely fetal origin was confirmed
for 56.4% and 6.4%, respectively. The genotyping result was
1072 VOSSAERT ET AL.uninformative or the assay failed for 35.1%. Four cells were confirmed
maternal.
In total, 38 samples out of 125 were shipped overnight from New
York to Houston, versus 87 samples recruited locally. On average 0.16
cells/mL were found for the first group compared with 0.18 cells/mL
for the latter; this difference was not statistically significant (P value:
0.616; unpaired t test, two tailed), showing that overnight shipment
did not pose a problem for trophoblast recovery.
In total, there were seven samples that were collected within a
few minutes to 2 hours after CVS or amniocentesis procedure. Within
this group, fetal cells were identified only in four samples: only one cell
was found for one post CVS and one postamnio sample, while two
other post CVS samples had 9 and 12 cells, respectively.
We investigated whether the maternal body mass index (BMI) had
an influence on the fetal cell yield (cells/mL). BMI data was available
for 103 samples and ranged from 18.90 to 45.89 kg/m2. No significant
correlation was found (Pearson r: 0.065; P value: 0.513). Although we
observed fewer trophoblasts with increasing gestational age, also
here, no significant correlation was found (Pearson r: −0.144; P value:
0.112).3.2 | Abnormal findings: Fetal aneuploidies
This sample series contained multiple cases with chromosomal abnor-
malities as detected by diagnostic prenatal testing. There were 15
cases with clinically reported fetal aneuploidies, including eight fetuses
with trisomy 21 (of which two were the result of a RobertsonianFIGURE 1 Detection of fetal aneuploidies. Panel A shows the single c
pregnancy in which the fetus had a 45,X chromosome complement. The w
fetal reference single cells. In Panel A, three cells are compared with a sing
change in Y. In Panel B, the same fetal cells are compared with a male refer
loss in the case versus the references in the polymorphic region of 15q11 ca
under the whole genome plots (comparison to female reference). Panel C s
with trisomy 21. For all figures, the NGS whole genome plots are displayed
Additional plots for each of these cases are shown in Figure S1 [Colour figtranslocation), four with trisomy 18, two cases with 45,X without
mosaicism, and one case with 47,XXY. We did not recover any fetal
cells for one of the translocation Down syndrome cases, two of the
trisomy 18 cases, and the 47,XXY case, but we found on average
4.27 cells/sample for the other 11 aneuploidy cases (0.18 cells/mL),
all collected between 12 and 18 weeks gestation. For all of these,
the cell‐based NIPT results were consistent with the diagnostic
results.
Panel A in Figure 1 shows one of the 45,X cases. This subject
underwent a CVS at 14 weeks and 2 days gestation, after ultrasound
examination showed fetal cystic hygroma, hydrops, pleural effusion,
echogenic bowel, and a nuchal translucency (NT) of 14 mm. Analysis
of the chorionic villus sample indicated a 45,X karyotype, as was also
seen in the sequencing data from three single fetal trophoblasts iso-
lated from a maternal blood sample obtained before the CVS proce-
dure was done. Two additional aneuploidy cases are shown in Panels
C and D: one female fetus with trisomy 18 and one male fetus with
trisomy 21, respectively. Additional data on each of these cases are
shown in Figure S1.3.3 | Abnormal findings: Subchromosomal variants
Additionally, there were five cases in this series with pathogenic
subchromosomal deletions or duplications, with a size range from
153 kb to 18.9 Mb. For each of the four cases with abnormalities of
greater than or equal to 1 Mb, fetal cells were isolated, and all CNVs
were identified by our cell‐based NIPT assay (shown in Figures 2–5)ell next‐generation sequencing (NGS) analysis on three cells from a
hole genome plots show the comparison of the fetal cells to normal
le normal female fetal cell, and the loss of X is visible (arrows), with no
ence showing a loss of Y (arrows) but no change for X. A copy number
n be seen in all plots (asterisk). A more detailed view of chr15 is shown
hows a female fetal cell with trisomy 18 and Panel D a male fetal cell
as 1 Mb bins and the detailed single chromosome plots as 100 kb bins.
ure can be viewed at wileyonlinelibrary.com]
FIGURE 2 Detection of an 18.9 Mb deletion on chromosome 4p and a smaller duplication on chromosome 15q in a female fetus. The cell‐based
noninvasive prenatal testing (NIPT) result is shown in Panel A and the amniocentesis result in Panel B. Chromosomal microarray (CMA) after
amniocentesis revealed an 18.9‐Mb deletion of 4p16.3p15.31 (Wolf‐Hirschhorn region) and a 1.1‐Mb gain of 15q13.1q13.2. The CMA
coordinates for the deletion are chr4:85,743‐18,953,893 and for the gain chr15:29,213,743‐30,300,265. The cell‐based NIPT data were
concordant with these amnio data [Colour figure can be viewed at wileyonlinelibrary.com]
FIGURE 3 Detection of a complex subchromosomal gain on chromosome 16p. Panels A and B show the cell‐based noninvasive prenatal testing
(NIPT) whole genome and chromosome 16 plot, respectively, of the comparison of a female fetal cell compared with a normal male reference. A
gain is seen on chromosome 16p. A single‐nucleotide polymorphisms (SNP) array comparative genomic hybridization (CGH) on a chorionic villus
sampling (CVS) sample as shown in Panel C, indicated a large complex 15 Mb gain of chromosome 16, with three duplications, three triplications,
and two quadruplications. The details of the subsections of the gain detected on array cannot be distinguished in the cell‐based NIPT data [Colour
figure can be viewed at wileyonlinelibrary.com]
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FIGURE 4 Detection of a 6.0‐Mb deletion of 1p35.1p34.3 in a male fetal cell. The whole genome plot for the cell‐based noninvasive prenatal
testing (NIPT) result is shown in Panel A, demonstrating the comparison to a female fetal reference cell with the X and Y chromosome
difference and showing a deletion on chromosome 1. The single chromosome 1 plot is shown in Panel B. The data are concordant with the
chorionic villus sampling (CVS) chromosomal microarray (CMA) data shown in Panel C. The coordinates for the deletion from the array were
chr1:33,058,933‐39,031,717 [Colour figure can be viewed at wileyonlinelibrary.com]
FIGURE 5 Detection of a 1.2‐Mb gain at Xp22.31. The cell‐based noninvasive prenatal testing (NIPT) whole genome plot with both the case and
the control being male is shown in Panel A, with a suggestion of a duplication on Xp. The single chromosome plot in Panel B confirms the gain.
Panel C shows the chromosomal microarray (CMA) result for the chorionic villus sampling (CVS) sample, and the array coordinates for the gain
were chrX:6,866,449‐8,115,153 [Colour figure can be viewed at wileyonlinelibrary.com]
1074 VOSSAERT ET AL.in concordance with the available microarray data from invasively
obtained fetal samples. For the case with a 153‐kb intragenic GPC3
deletion in Xq26.2q26.2, trophoblasts were identified but not
sequenced for incidental reasons.
Figure 2 shows a case in which a female fetus carried an 18.9‐Mb
loss of chromosome 4 (Wolf‐Hirschhorn region) and a 1.1‐Mb gain of
chromosome 15, detected by CMA on an amniocentesis sample
obtained at 33 weeks and 2 days. The maternal blood sample was col-
lected at 34 weeks and 4 days (>1 week after procedure). Despite the
advanced gestational age, three cells were isolated from maternalblood, for two of which the NGS data were consistent with the
CMA result, while sequencing failed for the third cell.
In another case (Figure 3), the mother underwent both CVS and
amniocentesis with subsequent CMA analysis, which revealed that
the female fetus harbored a complex 15‐Mb gain of chromosome
16, containing three duplications, two triplications, and two quadrupli-
cations. The blood sample for our study, from which eight cells were
isolated, was collected immediately before amniocentesis at 16 weeks
and 2 days. Even though the single cell NGS analysis could not resolve
the same detail in copy number changes, the cell‐based result clearly
VOSSAERT ET AL. 1075showed a similar result to the gain observed in the CMA data. The
serum screening for this case, performed as part of the patient's clini-
cal care, had indicated a one in five risk for Down syndrome and a first
trimester NT of 2.8 mm.
Figure 4 illustrates the whole genome plot from a male fetus with
a 6.0‐Mb loss of chromosome 1. The mother was of advanced mater-
nal age and ultrasound examination showed fetal cystic hygroma. A
CVS sample was collected at 13 weeks and 6 days, as well as a mater-
nal blood sample 1 hour after procedure for cell‐based NIPT. As we
could not recover any fetal trophoblastic cells from that sample, a
redraw was done at 15 weeks and 4 days, and NGS data obtained
from a trophoblast doublet from that sample were concordant with
the CMA result obtained earlier.
Figure 5 shows a case in which a 1.2‐Mb gain of the X chromo-
some was detected in both the male fetus and his carrier mother. This
sample was collected at 12 weeks and 1 day, before CVS. cfDNA‐
based NIPT was done for this pregnancy as well but gave no report-
able result because, as noted by the reported laboratory, “due to tech-
nical or sample‐related issues the data failed to meet the quality
standards for interpretation (the patient reportedly has a large fibroid
which is likely interfering with the analysis of the fetal DNA).”3.4 | Mosaicism
We encountered a case of possible confined placental mosaicism in
this data set. Study subject NIPT733 first underwent cfDNA‐based
NIPT, which indicated a “possible partial or full monosomy of chromo-
some 13.” The patient then underwent a CVS procedure with CMA
analysis on DNA directly extracted from the CVS sample, without
prior culture, which showed a normal result. Simultaneously, we
enrolled this subject for our study and were able to isolate three fetalFIGURE 6 Detection of two mosaic deletions on chromosome 13. For t
possible partial or full monosomy 13, while chromosome analysis of chorio
We retrieved three fetal trophoblastic cells of which two showed a normal
showed two small deletions of 4 Mb and 2.6 Mb (Panel C). The normal CVS
Panel D [Colour figure can be viewed at wileyonlinelibrary.com]trophoblastic cells. One of those clearly showed two small losses
(4 Mb and 2.6 Mb, respectively) on chromosome 13 (Figure 6), which
we interpret as likely related to the cfDNA‐based NIPT result and not
coincidental. The other cells did not show these deletions, implying
that confined placental mosaicism led to the false positive cfDNA‐
based NIPT result. This highlights the potential of cell‐based NIPT to
demonstrate two different fetal genotypes in case of mosaicism,
which cannot be achieved by cfDNA‐based testing.3.5 | Quality of single cell NGS data
In general, most isolated fetal cells yield NGS plots of adequate qual-
ity. Occasionally, however, we obtain NGS data of inferior quality,
usually associated with fetal cells for which only a weak DAPI signal
is observed during microscopic validation. Figure 7 illustrates the
whole genome plots for four cells isolated from the same sample: cell
G200 has a lower DAPI signal and shows extreme copy number loss
going to near zero copies for multiple large chromosome segments
(chr1, 9) or entire chromosomes (chr7, 8, 13, 15). As discussed below,
this was interpreted as apoptosis based on prior experience on such
profiles.14-16 Panel B in this figure illustrates the impact of pooling
the data of an apoptotic (G200) and a high‐quality cell (G1127):
although the pooled data show a less extreme profile compared with
G200 by itself, the overall data are unusable for CNV analysis.4 | DISCUSSION
The results presented here further support the feasibility of cell‐based
NIPT as a clinical test, in agreement with other publications.9-12 Our
data set represents the largest to date showing successful, reproduc-
ible analysis of single trophoblasts by NGS‐based CNV analysis withhis case, cfDNA‐based noninvasive prenatal testing (NIPT) indicated a
nic villus sampling (CVS) tissue showed a normal male pregnancy.
chromosome 13 content (Panels A and B). The third fetal cell, however,
chromosomal microarray (CMA) result for chromosome 13 is shown in
FIGURE 7 Segmental loss of copy number, including homozygous loss for entire chromosomes suggestive of apoptosis. The whole genome plots
for four cells from a male fetus compared with female fetal reference are shown in Panel A. The plot for cell G200 is extremely noisy while that of
the other three cells shows a normal male profile. The DAPI staining for this cell is faint compared with the other fetal (white arrows) and maternal
cells. The highly segmental loss of copy number including homozygous loss for entire chromosomes or arms of chromosomes as seen in cell G200
is interpreted to represent apoptosis (see Section 4). Panel B shows the substantial impact of pooling the data of an apoptotic cell (G200) with the
data of a cell of high quality (G1127): Even though the copy number changes seen for G200 are somewhat compensated by G1127, the overall
profile remains useless for copy number variant (CNV) analysis nevertheless. This next‐generation sequencing (NGS) plot was generated by
comparing this pool to a reference pool of two normal fetal cells [Colour figure can be viewed at wileyonlinelibrary.com]
1076 VOSSAERT ET AL.the goal of implementing a clinical cell‐based NIPT protocol. The major
obstacle that remains is obtaining a consistent fetal cell yield for each
sample. The goal of this study was primarily to develop and refine an
optimal protocol; thus, the diagnostic results are still exploratory and
preliminary, and further clinical validation is needed. We acknowledge
that the protocol is still evolving. Our ultimate goal for clinical testing
is to have excellent NGS data on three to five cells, but we have
observed cases for which a single cell provided valuable information.
Although 18.4% and 19.2% of the samples described here resulted
in zero or one cell recovered, previously published reports on
immunomagnetic bead enrichment indicate that fetal cell yield can
be further increased.10,11 Our own recent experience with a new pro-
tocol for positive trophoblast selection at present being explored in
our lab, supports this (unpublished data). Any manipulation before or
during the blood draw that could increase the number of trophoblasts
in the maternal circulation, such as physical activity before blood col-
lection, would also be helpful. However, exercise on a stationary bicy-
cle provided a small increase in cell number.17 Our data suggest that
trophoblast recovery is unlikely to be influenced by the maternalBMI that is known to be a cause for cfDNA‐based NIPT failure
because of its lowering effect on the fetal fraction. The effect of a
CVS/amniocentesis procedure on fetal cell yield for blood samples col-
lected postprocedure has been described for fnRBCs.18 In our series
the effect seems limited, but more samples are needed for statistical
comparison.
Although the isolated fetal cells have a distinct cytokeratin stain-
ing pattern that has been used to validate their fetal origin,11 we think
it is important to confirm fetal origin more conclusively when they are
used for clinical, diagnostic cell‐based NIPT. Confirming fetal origin
can be done by demonstrating the presence of an XY complement
by NGS for male pregnancies. It is more challenging for female preg-
nancies, where genotyping is require to differentiate them from
maternal cells that were incorrectly identified as likely fetal by
microscopy.
Multiple pregnancies represent both a challenge and a potential
strength for cell‐based NIPT. For example, for dizygous twins, it
should be possible to obtain reliable independent data from both
fetuses, assuming robust genotyping to distinguish cells from the
VOSSAERT ET AL. 1077two twins. In case of monozygous twins with identical CNV findings,
testing a larger number of cells offers increased statistical confidence
that both fetuses have been studied. For rare cases in which only
one of monozygous twins is carrying a de novo CNV, the two CNV
profiles should be distinguishable if enough cells are tested.
If more than one fetal cell is recovered from a maternal blood
sample, there is the option to analyze the cells individually, or as a pool
of cells. We prefer to analyze them as individual cells, even though this
slightly increases WGA and sequencing costs. Occasionally, tropho-
blast clusters (≥2 fetal cells together) are identified, and we speculate
that these may be recently released from the placenta and be daugh-
ter cells from a recent mitosis. When these clusters remain attached
during the picking procedure, they are analyzed as one. As WGA prod-
uct quality varies from cell to cell, we do not wish to risk compromis-
ing the NGS profile of one good quality cell by pooling with another
cell of inferior quality. For instance, pooling cells G200 and G1127
shown in Figure 7 give an unusable result, although cell G1127 alone
is useful. Since data from multiple single cells can also be pooled post
NGS and data analysis, we recommend against pooling cells before
WGA. Single trophoblast data can help to address mosaicism, as is
suggested by our current and earlier data, and they are also preferred
for multiple pregnancies.
Single cells with severe and often homozygous whole or segmental
chromosome loss as illustrated in Figure 7 are interpreted to represent
fetal cells undergoing apoptosis. Every apoptotic cell has its own unique
pattern of copy number changes (often to zero copies), affecting multi-
ple entire chromosomes. In contrast, a true CNV is seen in multiple cells
of confirmed fetal origin from the same sample. Kolialexi et al summa-
rized extensive evidence of apoptosis in fetal cells in the maternal circu-
lation including much higher apoptosis rates in Down syndrome and
Turner syndrome pregnancies.14 The apoptotic cells were suggested
to be a source of cfDNA in mother's plasma. Bártová used FISH and
TUNEL methods to demonstrate that “chromosomal territory segmen-
tation precedes the formation of nuclear apoptotic bodies.”15 Particu-
larly the chromosomal territory images shown in their publication15
lead us to interpret these fetal cells as apoptotic. Similar large homozy-
gous deletions were described in cancer cells and termed chromazemic
cells thatmight represent dying cells.16 NoTUNEL or Annexin V staining
was done in the study presented in this manuscript.
The new data reported here, combined with previously published
results, show that a broad range of fetal chromosomal abnormalities,
ranging from aneuploidies to subchromosomal gains or losses of
greater than or equal to1 to 2 Mb in size can be detected. In all cases
where useful NGS data were available except for one instance of pre-
sumed confined placental mosaicism, the findings in any fetal cell
agreed with the findings after amniocentesis or CVS, and for cases
where more than one fetal cells was scorable, the different cells
showed similar NGS plots. At this stage of development, the process-
ing time was lengthy, and the review of the NGS data was not blinded,
although blinding is currently being used. For the detection of CNVs in
fetal cells, it is desirable to have the highest resolution possible, so that
also (de novo) microdeletions/duplications are detected, such as the 2
to 3 Mb 22q11.2 deletion causing DiGeorge syndrome, the 1.5‐Mb
deletion causing Williams syndrome or the 1.5‐Mb CMT1A duplica-
tion. Reliable CNV detection at 220 kb resolution has been describedin single tumor cells by Casasent, Schalck , and Gao19 and a new WGA
method reported by Chen et al,20 reported the detection of micro
CNVs as small as 100 kb. From a clinical perspective, we believe that
CNV detection at 0.5 Mb is a reasonable short‐term goal for cell‐
based NIPT.
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